Abiopharma

New Form DEFA14A - Cardio Diagnostics Holdings, Inc. Filed: 2025-09-04 AccNo: 0001079973-25-001420 Size: 457 KB

IO Biotech, Inc. - IO Biotech Announces Participation in Upcoming Investor Conferences

IO Biotech Announces Participation in Upcoming Investor Conferences

Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment

CoyaTherapeutics - Coya Therapeutics COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial

electroCore Partners with iHeartRadio and Former New York Jets Star Linebacker Greg Buttle to Champion Better Sleep and Stress Relief

New Form 8-K - Lyra Therapeutics, Inc. Filed: 2025-09-04 AccNo: 0001193125-25-195384 Size: 2 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster

Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange

Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025

New Form DEF 14A - Cardio Diagnostics Holdings, Inc. Filed: 2025-09-04 AccNo: 0001079973-25-001419 Size: 901 KB

Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl

Daxor’s Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care

NanoVibronix Inc Notification (NAOV)

Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium